MPL and autoimmune thrombocytopenic purpura: The availability of the well tolerated, nonimmunosuppressive thrombopoietin receptor agonists (TPO-RAs), eltrombopag and romiplostim, as second line treatment options for ITP has started to shift the paradigm of ITP management and delay splenectomy [7, 10–13].